Novartis AG (SW:NOVN) — Stock Price

CHF126.80 CHF
▲ 0.65% today

Novartis AG (SW:NOVN) is currently trading at CHF126.80 CHF, up 0.65% today. Over the past 52 weeks, shares have ranged between CHF96.23 and CHF130.50. This page tracks Novartis AG's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NOVN market cap.

Novartis AG (NOVN) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Novartis AG's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.

Novartis AG Income Statement — Revenue, Profit & Earnings by Year

Novartis AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CHF57.13 Billion CHF51.72 Billion CHF46.66 Billion CHF43.46 Billion CHF43.97 Billion
Cost of Revenue CHF14.27 Billion CHF12.83 Billion CHF12.47 Billion CHF11.58 Billion CHF11.73 Billion
Gross Profit CHF42.86 Billion CHF38.90 Billion CHF34.19 Billion CHF31.88 Billion CHF32.24 Billion
Research & Development CHF11.20 Billion CHF10.02 Billion CHF11.37 Billion CHF9.17 Billion CHF8.64 Billion
SG&A CHF13.24 Billion CHF12.57 Billion CHF12.52 Billion CHF14.19 Billion CHF14.81 Billion
Total Operating Expenses CHF25.06 Billion CHF24.35 Billion CHF24.42 Billion CHF23.93 Billion CHF22.18 Billion
Operating Income CHF17.80 Billion CHF14.54 Billion CHF9.77 Billion CHF7.95 Billion CHF10.06 Billion
EBITDA CHF23.96 Billion CHF20.71 Billion CHF18.25 Billion CHF14.68 Billion CHF30.91 Billion
EBIT CHF18.38 Billion CHF14.65 Billion CHF9.98 Billion CHF7.98 Billion CHF25.32 Billion
Interest Expense CHF1.24 Billion CHF1.01 Billion CHF916.86 Million CHF860.20 Million CHF904.83 Million
Income Before Tax CHF17.13 Billion CHF13.64 Billion CHF9.12 Billion CHF7.18 Billion CHF24.53 Billion
Income Tax Expense CHF2.50 Billion CHF1.70 Billion CHF551.00 Million CHF1.13 Billion CHF1.62 Billion
Net Income CHF14.65 Billion CHF11.94 Billion CHF14.85 Billion CHF6.96 Billion CHF24.02 Billion

Novartis AG Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Novartis AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CHF115.49 Billion CHF102.25 Billion CHF99.94 Billion CHF117.45 Billion CHF131.79 Billion
Total Current Assets CHF30.44 Billion CHF29.70 Billion CHF30.48 Billion CHF36.91 Billion CHF45.72 Billion
Cash & Equivalents CHF8.86 Billion CHF8.87 Billion CHF10.19 Billion CHF4.64 Billion CHF9.01 Billion
Short-term Investments CHF154.90 Million CHF1.89 Billion CHF569.00 Million CHF11.10 Billion CHF15.71 Billion
Net Receivables CHF10.93 Billion CHF9.54 Billion CHF9.38 Billion CHF9.89 Billion CHF9.62 Billion
Inventory CHF6.26 Billion CHF5.72 Billion CHF5.91 Billion CHF7.17 Billion CHF6.67 Billion
Property, Plant & Equipment CHF12.35 Billion CHF10.87 Billion CHF10.92 Billion CHF12.20 Billion CHF13.11 Billion
Goodwill CHF25.55 Billion CHF24.76 Billion CHF23.34 Billion CHF29.30 Billion CHF29.59 Billion
Total Liabilities CHF68.97 Billion CHF58.12 Billion CHF53.20 Billion CHF58.03 Billion CHF63.97 Billion
Total Current Liabilities CHF27.26 Billion CHF28.69 Billion CHF26.39 Billion CHF28.66 Billion CHF30.21 Billion
Long-term Debt CHF27.93 Billion CHF21.37 Billion CHF18.44 Billion CHF20.24 Billion CHF22.90 Billion
Net Debt CHF25.58 Billion CHF19.80 Billion CHF12.96 Billion CHF20.39 Billion CHF18.62 Billion
Total Stockholder Equity CHF46.10 Billion CHF44.05 Billion CHF46.67 Billion CHF59.34 Billion CHF67.66 Billion
Retained Earnings CHF44.69 Billion CHF46.56 Billion CHF49.65 Billion CHF63.54 Billion CHF70.99 Billion

Novartis AG Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Novartis AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CHF20.05 Billion CHF17.62 Billion CHF14.46 Billion CHF14.24 Billion CHF15.07 Billion
Capital Expenditures CHF1.62 Billion CHF3.81 Billion CHF2.75 Billion CHF2.67 Billion CHF2.97 Billion
Free Cash Flow CHF18.43 Billion CHF13.80 Billion CHF11.71 Billion CHF11.56 Billion CHF12.10 Billion
Investing Cash Flow CHF-5.11 Billion CHF-7.51 Billion CHF5.60 Billion CHF1.47 Billion CHF4.21 Billion
Financing Cash Flow CHF-15.57 Billion CHF-11.74 Billion CHF-14.28 Billion CHF-20.56 Billion CHF-16.26 Billion
Dividends Paid CHF8.19 Billion CHF7.62 Billion CHF7.25 Billion CHF7.51 Billion CHF7.37 Billion
Stock-Based Compensation CHF1.10 Billion CHF1.04 Billion CHF865.00 Million CHF791.00 Million CHF700.00 Million
Depreciation CHF5.58 Billion CHF6.07 Billion CHF8.28 Billion CHF7.18 Billion CHF6.11 Billion
Change in Cash CHF-1.67 Billion CHF-1.93 Billion CHF5.88 Billion CHF-4.89 Billion CHF2.75 Billion

Novartis AG Earnings History — EPS Actual vs. Analyst Estimates

Track Novartis AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Apr 28, 2026 1.29 2.08 -37.94%
Feb 04, 2026 2.03 2.07 -1.93%
Oct 28, 2025 2.04 1.87 +9.09%
Jul 17, 2025 2.42 2.37 +2.11%
Apr 29, 2025 2.28 2.15 +6.05%
Jan 30, 2025 1.98 1.82 +8.79%
Oct 28, 2024 2.06 1.94 +6.19%
Jul 17, 2024 1.97 1.87 +5.35%